News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
Subscribe To Our Newsletter & Stay Updated
